Navigation Links
Genomic Health to Present at Piper Jaffray Health Care Conference
Date:11/24/2009

REDWOOD CITY, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Randy Scott, Genomic Health's Executive Chairman, will present at the 21st Annual Piper Jaffray Health Care Conference in New York City on Tuesday, December 1, 2009 at 10:00 a.m. ET.

To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in the first quarter of 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Vincent R. Burton, MBBS, FRCA, ... licensed by the Bahamas’ National Stem Cell Ethics Committee (NSCEC). , Dr. Burton ... the West Indies. He went on to complete residency training in the United Kingdom ...
(Date:7/26/2017)... ... July 25, 2017 , ... Avery Products ... that enable short-run digital printing, is proud to announce that it has won ... Wizard online software available at avery.com/GHS . The products were recently honored ...
(Date:7/26/2017)... , ... July 25, 2017 , ... ... and manufacturing services that are necessary in the preparation and development of human ... biorepository facility operates under the US Food and Drug Administration’s (FDA) Current Good ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... company for the improvement of crop productivity and economics for the food, feed ... The scope of the agreement includes the research and development of microbiome-based seed ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):